Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark - internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. It's a dual listed company with shares traded on the Copenhagen Stock Exchange in Denmark, and on NASDAQ Global Select Market in the US.The company has 3 approved antibodies used in 5 marketed products, covering cancer indications and autoimmune diseases:

DARZALEX (IV) (daratumumab) for the treatment of all stages of multiple myeloma as combination therapy or monotherapy
DARZALEX FASPRO (SC) (daratumumab and hyaluronidase-fihj) approved in many of the same indications as DARZALEX (IV)
Arzerra (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications
Kesimpta (ofatumumab) for the treatment of relapsing remitting multiple sclerosis
TEPEZZA (teprotumumab-trbw) for the treatment of thyroid eye disease (TED)Futhermore daratumumab is in clinical development for AL amyloidosis and for Non-MM blood cancers, and teprotumumab is in clinical development for diffuse cutaneous systemic sclerosis.
Besides these 3 antibodies the company has a broad clinical and pre-clinical pipeline of antibody products.